Your session is about to expire
← Back to Search
Chemotherapy + Paricalcitol for Pancreatic Cancer (NABPLAGEMD Trial)
NABPLAGEMD Trial Summary
This trial is testing a new combination of drugs to see if it's effective in treating pancreatic cancer that has spread.
NABPLAGEMD Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.NABPLAGEMD Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You had cancer in the past, except for certain types that have been cured or have not shown up for at least two years.You had surgery or radiation treatment for symptom relief less than 4 weeks ago.
- Group 1: Paricalcitol (Zemplar)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has Paricalcitol (Zemplar) received FDA sign-off?
"Paricalcitol (Zemplar) is currently being trialled in Phase 2, so there is some safety data supporting its use but efficacy has not yet been proven."
What is the maximum participation for this clinical trial?
"Presently, this clinical trial is not searching for new patients. This specific study was posted on 1/31/2018 and last edited on 2/16/2022. However, there are 1175 other trials for adenocarcinoma and 1564 trials for Paricalcitol (Zemplar) that are still recruiting patients."
Can people with the qualifying condition participate in this research?
"This particular clinical trial is not looking for new patients at the moment, however that could change in the future. The last update on this study was February 16th, 2022 and it was originally posted January 31st, 2018. There are 2,739 other trials that are currently open to new participants."
What is the primary purpose of Paricalcitol (Zemplar)?
"Paricalcitol (Zemplar) is most often used as part of adjuvant therapy for patients that have already undergone treatment with anthracyclines. Additionally, this medication can be given to patients suffering from neoplasm metastasis, locally advanced non-small cell lung cancer, and metastatic bladder cancer."
Share this study with friends
Copy Link
Messenger